2 FDA Meetings re P3 Tovaxin® Clinical Multiple Sclerosis Study, Opexa (OPXA)
January 5th, 2011
No comments
OPXA’s Tovaxin® for multiple sclerosis (MS) completed 2 separate and successfull meetings with the FDA regarding the development program for Tovaxin. Read more…
